Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Palau Pharma General Information
Palau Pharma has developed a portfolio of approximately ten projects targeting inflammatory and autoimmune conditions. Four reached late-stage clinical development or registration/marketing phases. Some assets have been outlicensed to other companies for further development and commercialization. For example, POLB001 was licensed to Poolbeg Pharma for further clinical advancement.
Contact Information
Primary Industry
Biotech
Corporate Office
Barcelona / Palau Solità i Plegamans,
Spain
Spain
Drug Pipeline
albaconazole
Phase 2Key Partnerships
GlaxoSmithKline, Schering-Plough, Affectis Pharmaceuticals, IberHospitex, Poolbeg Pharma
Palau Pharma Funding
No funding data available
To view Palau Pharma's complete valuation and funding history, request access »